The Department of Justice spooked the living daylights out of corporate legal and regulatory compliance teams at this time last year.

That’s when it withdrew long-standing “safety zones” guidance, which gave health care competitors leeway to exchange certain kinds of information without fear that regulators would pounce, charging collusion or other antitrust violations.